## Chawla-Rosenfeld Developmental Therapeutics Symposium: 3:30-4:50 pm ET

### Sarcoma Origins: Predisposition and Precursors

<table>
<thead>
<tr>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| Introduction | Jonathan Fletcher, MD (SARC CSO)  
Brigham and Women’s Hospital - DF/HCC |
| Mapping and management of genetic risk in the sarcoma population | David Thomas, FRACP, PhD  
Garvan Institute of Medical Research |
| LMS oncogenesis: from tumor cells to normal cells | Elodie Darbo, PhD  
University of Bordeaux |
| Advances in early detection of malignant transformation of peripheral nerve sheath tumors in NF1 | Brigitte Widemann, MD  
National Cancer Institute |

**Panel Discussion / Q & A**

- David Thomas, FRACP, PhD
- Elodie Darbo, PhD
- Frédéric Chibon, PhD (CRCT-ONCOPOLE)
- Brigitte Widemann, MD

**Closing Comments**

**Moderators:**

- Joshua Schiffman, MD  
Huntsman Cancer Institute
- Irene Andrulis, PhD  
University of Toronto
- Jonathan Fletcher, MD (SARC CSO)

## SARC Research Initiatives: 4:50-5:30 pm ET

**Introduction: Currently Enrolling SARC Clinical Trials**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Title</th>
<th>PI</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARC037</td>
<td>Phase I Trabectedin in Ewing Sarcoma in Combination with Irinotecan and 18F-FLT Imaging</td>
<td>Patrick Grohar, MD, PhD</td>
<td>Children’s Hospital of Philadelphia</td>
</tr>
<tr>
<td>SARC031</td>
<td>Phase 2 MEK inhibitor selumetinib w/ dual mTOR kinase inhibitor sirolimus in MPNST</td>
<td>AeRang Kim, MD, PhD</td>
<td>Children’s National Medical Center</td>
</tr>
<tr>
<td>SARC032</td>
<td>Phase 2 Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Soft Tissue Sarcoma of the Extremity</td>
<td>David Kirsch, MD, PhD</td>
<td>Duke University</td>
</tr>
<tr>
<td>SARC038</td>
<td>Phase 2 Regorafenib in Combination with Nivolumab in Osteosarcoma</td>
<td>Lara Davis, MD</td>
<td>Oregon Health Sciences University</td>
</tr>
<tr>
<td>SARC041</td>
<td>Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS</td>
<td>Mark Dickson, MD</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
</tbody>
</table>

**SARC Principal Investigators / Q & A**

**Moderators & Closing Remarks:**

- Jonathan Fletcher, MD (SARC CSO)
- Steven Young (SARC President & CEO)